IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production.
Interferon-gamma (IFN-gamma) treatment increases osteoclastic bone resorption in vivo in patients with malignant osteopetrosis (OP). The treatment effect was studied in vitro in osteoclasts generated by culturing peripheral white blood cells (PWBC) from OP patients and normal human control subjects. Osteoclasts were treated with or without IFN-gamma prior to the end of the culture period. Osteoclasts from normal subjects were large in size (161 +/- 18 microm in diameter) with >10 nuclei per osteoclast. These cells showed intense staining for tartrate-resistant acid phosphatase (TRAP), expressed abundant calcitonin receptors (CTR), and formed numerous resorption pits on bovine bone slices, indicative of authentic osteoclasts. In contrast, similarly cultured osteoclasts from OP patients were smaller in size (18 +/- 3 microm in diameter), with 2-3 nuclei per osteoclast, and stained lightly for TRAP. However, IFN-gamma treatment of osteoclasts from OP patients resulted in the formation of larger osteoclasts (171 +/- 33 microm in diameter) with >10 nuclei per cell, similar in appearance to osteoclasts from normal subjects. IFN-gamma stimulation increased the intensity of TRAP staining (p < 0.0001) to levels near that of the normal osteoclasts. Unstimulated osteoclasts from 6 OP patients had a significantly lower baseline level of superoxide production, as measured by nitroblue tetrazolium reduction (p < 0.0001), compared with normal osteoclasts. IFN-gamma markedly increased (p < 0.0001) superoxide production. Whereas there was a 3-fold increase in superoxide generation in OP patients' osteoclasts, osteoclasts from control subjects had only a small and insignificant increase in superoxide production after IFN-gamma treatment.
Madyastha
P R
PR
Department of Pediatrics, Medical University of South Carolina, Charleston 29425, USA.
Yang
S
S
Ries
W L
WL
Key
L L
LL
D000135:Acid Phosphatase / Q000032:analysis; D000328:Adult; D000818:Animals; D002116:Calcitonin / Q000378:metabolism; D002117:Calcitriol / Q000494:pharmacology; D002417:Cattle; D002454:Cell Differentiation; D048429:Cell Size; D002478:Cells, Cultured; D002675:Child, Preschool; D003470:Culture Media; D003907:Dexamethasone / Q000494:pharmacology; D006801:Humans; D007223:Infant; D007371:Interferon-gamma / Q000494:pharmacology*; D007527:Isoenzymes / Q000032:analysis; D007963:Leukocytes, Mononuclear / Q000166:cytology* / Q000187:drug effects / Q000473:pathology; D016173:Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D010010:Osteoclasts / Q000166:cytology* / Q000187:drug effects; D010022:Osteopetrosis / Q000097:blood*; D018003:Receptors, Calcitonin / Q000032:analysis; D012016:Reference Values; D013481:Superoxides / Q000378:metabolism*; D000071681:Tartrate-Resistant Acid Phosphatase
D003470:Culture Media; D007527:Isoenzymes; D018003:Receptors, Calcitonin; D013481:Superoxides; D003907:Dexamethasone; D016173:Macrophage Colony-Stimulating Factor; D007371:Interferon-gamma; D002116:Calcitonin; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D002117:Calcitriol